ProBio, a global contract development and manufacturing organization (CDMO), is pleased to announce the launch of its GMP Plasmid DNA manufacturing service at its state-of-the-art facility in Hopewell. This new service guarantees the delivery of clinical-grade plasmid DNA production from cell bank to batch release in just three months. This is a significantly faster manufacturing time than is typical and can help accelerate the development of gene and cell therapies.
The Hopewell facility, which has a rich legacy of biologics innovation, previously served as a research hub for a leading global pharmaceutical company and later as an AAV-based gene therapy manufacturing center. Now the centerpiece of ProBio’s operations, the site is led by a team of industry veterans with decades of experience in biologics and cell and gene therapies. By combining this expertise with ProBio’s proprietary platform technologies, the company ensures fast, high-quality, and consistently reliable integrated end-to-end capabilities—from plasmid DNA production to drug product fill and finish.
Strategically located to serve both the U.S. and European markets, the Hopewell facility offers a seamless, fully integrated approach to manufacturing. ProBio’s expertise in process development, in-house analytical testing, method development, and project management team, minimizes the need for multiple suppliers, significantly accelerating development timelines.
